Standard

Symmetric dimethylguanidino valeric acid (SDGV), a novel single biomarker of hepatic steatosis. / Rodionov, R.N.; Koay, Y.C.; Jarzebska, N.; Markov, A.G.

In: iScience, Vol. 27, No. 12, 111366, 20.12.2024.

Research output: Contribution to journal › Article › peer-review

Harvard

Rodionov, RN, Koay, YC, Jarzebska, N & Markov, AG 2024, 'Symmetric dimethylguanidino valeric acid (SDGV), a novel single biomarker of hepatic steatosis', iScience, vol. 27, no. 12, 111366. https://doi.org/10.1016/j.isci.2024.111366

APA

Rodionov, R. N., Koay, Y. C., Jarzebska, N., & Markov, A. G. (2024). Symmetric dimethylguanidino valeric acid (SDGV), a novel single biomarker of hepatic steatosis. iScience, 27(12), [111366]. https://doi.org/10.1016/j.isci.2024.111366

Vancouver

Rodionov RN, Koay YC, Jarzebska N, Markov AG. Symmetric dimethylguanidino valeric acid (SDGV), a novel single biomarker of hepatic steatosis. iScience. 2024 Dec 20;27(12). 111366. https://doi.org/10.1016/j.isci.2024.111366

Author

Rodionov, R.N. ; Koay, Y.C. ; Jarzebska, N. ; Markov, A.G. / Symmetric dimethylguanidino valeric acid (SDGV), a novel single biomarker of hepatic steatosis. In: iScience. 2024 ; Vol. 27, No. 12.

BibTeX

@article{e852436ff552497ab7369301871ad3dd,
title = "Symmetric dimethylguanidino valeric acid (SDGV), a novel single biomarker of hepatic steatosis",
abstract = "There is an unmet need for a biomarker of liver fat. We identified dimethylguanidino valeric acid (DMGV) as a circulating biomarker of liver fat. Here, we assess its two isoforms - symmetric (SDGV) and asymmetric (ADGV) - as biomarkers of steatosis. We determined plasma ADGV, SDGV, related metabolites, alanine aminotransferase (ALT), and the fatty liver index (FLI) in two cohorts and compared their diagnostic performance for liver fat detection. SDGV was the strongest predictor of moderate to severe steatosis. Changes in SDGV correlated with changes in liver fat % in a prospective cohort. In a murine model of fatty liver disease, protein levels and activity of alanine:glyoxylate aminotransferase 2 (AGXT2), which produces SDGV, were increased and coincided with elevation of SDGV concentrations. SDGV is a biomarker of liver fat and its increase in hepatic steatosis results from the upregulation of AGXT2 activity.",
keywords = "Clinical finding, Health sciences, Physiological state",
author = "R.N. Rodionov and Y.C. Koay and N. Jarzebska and A.G. Markov",
note = "Rodionov, R.N., Jarzebska, N., Koay, Y.C., Li, M., Kuhn, M., Bornstein, S.R., Martens-Lobenhoffer, J., Eslam, M., Chen, F.W., Rubets, E., Markov, A.G., Weiss, N., Birkenfeld, A., Schwarz, P., Bode-B{\"o}ger, S.M., Perakakis, N., O{\textquoteright}Sullivan, J.F., George, J., Symmetric dimethylguanidino valeric acid (SDGV), a novel single biomarker of hepatic steatosis, ISCIENCE (2024), doi: https://doi.org/10.1016/j.isci.2024.111366",
year = "2024",
month = dec,
day = "20",
doi = "10.1016/j.isci.2024.111366",
language = "English",
volume = "27",
journal = "iScience",
issn = "2589-0042",
publisher = "Cell Press",
number = "12",

}

RIS

TY - JOUR

T1 - Symmetric dimethylguanidino valeric acid (SDGV), a novel single biomarker of hepatic steatosis

AU - Rodionov, R.N.

AU - Koay, Y.C.

AU - Jarzebska, N.

AU - Markov, A.G.

N1 - Rodionov, R.N., Jarzebska, N., Koay, Y.C., Li, M., Kuhn, M., Bornstein, S.R., Martens-Lobenhoffer, J., Eslam, M., Chen, F.W., Rubets, E., Markov, A.G., Weiss, N., Birkenfeld, A., Schwarz, P., Bode-Böger, S.M., Perakakis, N., O’Sullivan, J.F., George, J., Symmetric dimethylguanidino valeric acid (SDGV), a novel single biomarker of hepatic steatosis, ISCIENCE (2024), doi: https://doi.org/10.1016/j.isci.2024.111366

PY - 2024/12/20

Y1 - 2024/12/20

N2 - There is an unmet need for a biomarker of liver fat. We identified dimethylguanidino valeric acid (DMGV) as a circulating biomarker of liver fat. Here, we assess its two isoforms - symmetric (SDGV) and asymmetric (ADGV) - as biomarkers of steatosis. We determined plasma ADGV, SDGV, related metabolites, alanine aminotransferase (ALT), and the fatty liver index (FLI) in two cohorts and compared their diagnostic performance for liver fat detection. SDGV was the strongest predictor of moderate to severe steatosis. Changes in SDGV correlated with changes in liver fat % in a prospective cohort. In a murine model of fatty liver disease, protein levels and activity of alanine:glyoxylate aminotransferase 2 (AGXT2), which produces SDGV, were increased and coincided with elevation of SDGV concentrations. SDGV is a biomarker of liver fat and its increase in hepatic steatosis results from the upregulation of AGXT2 activity.

AB - There is an unmet need for a biomarker of liver fat. We identified dimethylguanidino valeric acid (DMGV) as a circulating biomarker of liver fat. Here, we assess its two isoforms - symmetric (SDGV) and asymmetric (ADGV) - as biomarkers of steatosis. We determined plasma ADGV, SDGV, related metabolites, alanine aminotransferase (ALT), and the fatty liver index (FLI) in two cohorts and compared their diagnostic performance for liver fat detection. SDGV was the strongest predictor of moderate to severe steatosis. Changes in SDGV correlated with changes in liver fat % in a prospective cohort. In a murine model of fatty liver disease, protein levels and activity of alanine:glyoxylate aminotransferase 2 (AGXT2), which produces SDGV, were increased and coincided with elevation of SDGV concentrations. SDGV is a biomarker of liver fat and its increase in hepatic steatosis results from the upregulation of AGXT2 activity.

KW - Clinical finding

KW - Health sciences

KW - Physiological state

UR - https://www.mendeley.com/catalogue/6a3c76a7-b43e-3d90-9dd5-d830f4c4306b/

U2 - 10.1016/j.isci.2024.111366

DO - 10.1016/j.isci.2024.111366

M3 - Article

C2 - 39660051

VL - 27

JO - iScience

JF - iScience

SN - 2589-0042

IS - 12

M1 - 111366

ER -

ID: 127186825